Fovea Pharmaceuticals SA
Quick facts
Marketed products
- PA · Ophthalmology
PA is a prodrug that is converted to its active form to modulate retinal function and treat vision disorders.
Phase 2 pipeline
- CsA high dose · Immunology
Calcineurin inhibitor - CsA low dose · Immunology
CsA works by inhibiting calcineurin, a protein phosphatase involved in the activation of T-lymphocytes. - FOV1101-00 · Ophthalmology
FOV1101-00 is a small molecule that targets retinal degeneration through modulation of cellular survival pathways in the eye.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: